Product Description
For the Treatment of Limbal Stem Cell Deficiency Associated With Neurotrophic Keratopathy (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04552730)
Mechanisms of Action: NGF Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Canada | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Netherlands | Poland | Portugal | Slovakia | Spain | Sweden | Switzerland | United Kingdom | United States
Approved Indications: Keratitis
Known Adverse Events: Hyperemia | Eye Pain | Pain Unspecified | Inflammation | Pregnancy Outcomes
Company: Dompe
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Italy, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| - | P3 |
Active, not recruiting |
Keratoconjunctivitis Sicca|Dry Eye Disease |
2023-10-24 |
|
| NGF0221 | P3 |
Completed |
Dry Eye Syndromes|Keratoconjunctivitis Sicca|Dry Eye Disease |
2023-03-02 |
|
| NGF0121 | P3 |
Active, not recruiting |
Dry Eye Syndromes|Keratoconjunctivitis Sicca|Dry Eye Disease |
2023-02-03 |
|
| NGF0221 | P3 |
Active, not recruiting |
Keratoconjunctivitis Sicca|Dry Eye Disease |
2022-12-15 |